Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

被引：40

作者：

So, Brian J. ^{[1
]}

Bekaii-Saab, Tanios ^{[1
]}

Bloomston, Mark A. ^{[1
]}

Patel, Tushar ^{[1
]}

机构：

[1] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2008年 / 1卷 / 1期

关键词：

Renal Cell Carcinoma; Complete Remission; Sorafenib; Gastrointestinal Stromal Tumor; Hemochromatosis;

D O I：

10.1186/1756-8722-1-18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

引用

页数：3

共 5 条

[1] Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Chang, Yong S.
Adnane, Jalila
Trail, Pamela A.
Levy, Joan
Henderson, Arris
Xue, Dahai
Bortolon, Elizabeth
Ichetovkin, Marina
Chen, Charles
McNabola, Angela
Wilkie, Dean
Carter, Christopher A.
Taylor, Ian C. A.
Lynch, Mark
Wilhelm, Scott
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) : 561 - 574
[2] Sorafenib in advanced hepatocellular carcinoma
Llovet, Josep M.
Ricci, Sergio
Mazzaferro, Vincenzo
Hilgard, Philip
Gane, Edward
Blanc, Jean-Frederic
Cosme de Oliveira, Andre
Santoro, Armando
Raoul, Jean-Luc
Forner, Alejandro
Schwartz, Myron
Porta, Camillo
Zeuzem, Stefan
Bolondi, Luigi
Greten, Tim F.
Galle, Peter R.
Seitz, Jean-Francois
Borbath, Ivan
Haussinger, Dieter
Giannaris, Tom
Shan, Minghua
Moscovici, Marius
Voliotis, Dimitris
Bruix, Jordi
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) : 378 - 390
[3] Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials
Lopez, P. M.
Villanueva, A.
Llovet, J. M.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (11) : 1535 - 1547
[4] Global cancer statistics, 2002
Parkin, DM
Bray, F
Ferlay, J
Pisani, P
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) : 74 - 108
[5] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Wilhelm, SM
Carter, C
Tang, LY
Wilkie, D
McNabola, A
Rong, H
Chen, C
Zhang, XM
Vincent, P
McHugh, M
Cao, YC
Shujath, J
Gawlak, S
Eveleigh, D
Rowley, B
Liu, L
Adnane, L
Lynch, M
Auclair, D
Taylor, I
Gedrich, R
Voznesensky, A
Riedl, B
Post, LE
Bollag, G
Trail, PA
[J]. CANCER RESEARCH, 2004, 64 (19) : 7099 - 7109

← 1 →